Semaglutide Patent Expiry and Opportunities for the Indian Pharmaceutical Sector

#GS-2 #GS-3 #Health #Economy #Science & Technology #Indian Polity & Constitution #National #Intellectual Property Rights

Why in News

The patent for **Novo Nordisk's** drug **Semaglutide** is expiring soon in India. This change allows domestic drug makers to produce affordable generic versions of **GLP-1** receptor agonist medicines.
**GLP-1** receptor agonists are specialized drugs that act like the human body's natural gut hormone called **GLP-1**.
These medications stimulate insulin release and slow down digestion in the stomach. As a result, they help patients control blood sugar levels, lower their appetite, and manage body weight effectively.

**Novo Nordisk's** original drug **Semaglutide** serves as a **GLP-1** receptor agonist designed specifically to treat **Type-2 Diabetes** and clinical obesity.
The medicine lowers blood glucose levels effectively while supporting steady weight reduction and protecting patients against major cardiovascular risks.
This therapy has revolutionized the medical management of **Type-2 Diabetes** and obesity, which are two leading contributors to non-communicable diseases globally.
Before this patent period ended, the high cost of branded **Semaglutide** kept this critical treatment out of reach for many patients.
The upcoming patent expiry will lower medicine costs, broaden public access to quality care, and expand the domestic drug manufacturing market.

India currently has over **10 crore** citizens living with diabetes along with a rising obesity burden. Generic versions of **Semaglutide** will drastically lower treatment expenses for these patients.
Patent expirations in nations like **China**, **Brazil**, **Canada**, **South Africa**, and **Turkey** create lucrative export channels for Indian generic manufacturers.
Making generic **Semaglutide** helps Indian drug companies upgrade from simple small-molecule drugs to complex peptide therapies and novel delivery devices.
Stronger domestic demand paired with support from the **Production Linked Incentive (PLI)** scheme will accelerate investments in research, active pharmaceutical ingredients, and advanced medicine production.

Beyond economic advantages, **GLP-1** receptor agonist drugs influence overall body health, showing notable clinical impacts on skin and hair condition.
Fast weight loss from these drugs can cause facial fat loss known informally as **Ozempic face**, while loose body skin may trigger skin infections like **intertrigo** and dark patches.
Rapid weight loss places physical stress on the body and can deplete essential nutrients like protein, iron, and **Vitamin B12**, leading to temporary hair shedding known as **Telogen Effluvium**.
Shifts in nutritional absorption during treatment frequently show up on nails, making them brittle, ridged, and slow-growing.
Early clinical studies suggest these drugs reduce systemic inflammation, which might help relieve skin diseases like **Psoriasis** and **Hidradenitis Suppurativa** in patients with metabolic disorders.

A patent acts as a legal protection given by the government to an inventor for **20 years** in exchange for disclosing technical details publicly.
This ownership right gives the patent holder exclusive control to manufacture, market, sell, license, or import the patented product.
Once the **20-year** tenure ends or official renewal fees remain unpaid, the invention becomes part of the public domain for everyone to use freely.

India introduced its first patent legislation through **Act VI of 1856**, followed by statutory updates in **1859**, **1872**, and finally the **Indian Patents and Designs Act, 1911**, which created the position of **Controller of Patents**.
Independent India reviewed its framework through the **Bakshi Tek Chand Committee (1949)** and the **Justice N. Rajagopala Ayyangar Committee (1959)**, culminating in the **Patents Act, 1970** that authorized process patents to help domestic generic drug production.
Joining the **WTO** in **1995** led India to amend its patent rules through the **Patents (Amendment) Act, 1999** for the Mailbox System, the **Patents (Amendment) Act, 2002** for 20-year terms, and the **Patents (Amendment) Act, 2005** for product patents.
Under the **Patents (Amendment) Act, 2005**, **Section 3(d)** prevents pharmaceutical companies from evergreening patents unless a minor modification shows significantly higher therapeutic efficacy.
Recent legal updates include the **Tribunals Reforms Act, 2021**, which dissolved the **Intellectual Property Appellate Board (IPAB)**, and the **Jan Vishwas Act, 2023** alongside the **Patents (Amendment) Rules, 2024** to speed up application checks from **48 to 31 months**.

When **Pfizer** lost its patent for the cholesterol drug **Lipitor** (**Atorvastatin**) in **2011**, Indian firms expanded rapidly into American and European cardiovascular drug markets.
The **2012** patent expirations for **Plavix** (**Clopidogrel**) and **Viagra** (**Sildenafil**) allowed domestic companies to boost manufacturing volumes and provide low-cost treatments globally.
In **2013**, the **Supreme Court of India** delivered a historic ruling against **Novartis** to stop patent evergreening on the leukemia drug **Imatinib**, cutting annual treatment costs from **USD 25,000** to a tiny fraction.
Patent changes surrounding the **Hepatitis C** medicine **Sofosbuvir** in **2025** further cemented India's global reputation as the **Pharmacy of the Developing World**.

**Why is the expiry of Semaglutide's patent significant for India?** It allows domestic drug makers to introduce low-cost **GLP-1** remedies, lowering healthcare bills for millions while spurring export opportunities.
**What are GLP-1 receptor agonists?** These are medications that manage **Type-2 Diabetes** and obesity by promoting insulin production, curbing appetite, supporting weight loss, and protecting heart health.
**How can Semaglutide strengthen India's pharmaceutical industry?** Producing generic **Semaglutide** boosts pharmaceutical exports, accelerates the adoption of complex peptide technologies, and drives new investments into research and active raw materials.